Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade

An analysis of RTOG 8610

Alan Pollack, D. J. Grignon, K. H. Heydon, E. H. Hammond, C. A. Lawton, J. B. Mesic, K. K. Fu, A. T. Porter, R. A. Abrams, W. U. Shipley

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70% for those with diploid tumors and 42% for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.

Original languageEnglish
Pages (from-to)1238-1248
Number of pages11
JournalJournal of Clinical Oncology
Volume21
Issue number7
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Salvage Therapy
Ploidies
Androgens
Prostatic Neoplasms
Radiotherapy
Hormones
DNA
Survival
Neoplasm Metastasis
Diploidy
Neoplasms
Radiation Oncology
Kaplan-Meier Estimate
Clinical Protocols
Random Allocation
Multivariate Analysis
Retrospective Studies
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade : An analysis of RTOG 8610. / Pollack, Alan; Grignon, D. J.; Heydon, K. H.; Hammond, E. H.; Lawton, C. A.; Mesic, J. B.; Fu, K. K.; Porter, A. T.; Abrams, R. A.; Shipley, W. U.

In: Journal of Clinical Oncology, Vol. 21, No. 7, 01.04.2003, p. 1238-1248.

Research output: Contribution to journalArticle

Pollack, Alan ; Grignon, D. J. ; Heydon, K. H. ; Hammond, E. H. ; Lawton, C. A. ; Mesic, J. B. ; Fu, K. K. ; Porter, A. T. ; Abrams, R. A. ; Shipley, W. U. / Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade : An analysis of RTOG 8610. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 7. pp. 1238-1248.
@article{81d4359a386b47ad9419e0da199d5d65,
title = "Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610",
abstract = "Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70{\%} for those with diploid tumors and 42{\%} for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.",
author = "Alan Pollack and Grignon, {D. J.} and Heydon, {K. H.} and Hammond, {E. H.} and Lawton, {C. A.} and Mesic, {J. B.} and Fu, {K. K.} and Porter, {A. T.} and Abrams, {R. A.} and Shipley, {W. U.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1200/JCO.2003.02.025",
language = "English",
volume = "21",
pages = "1238--1248",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade

T2 - An analysis of RTOG 8610

AU - Pollack, Alan

AU - Grignon, D. J.

AU - Heydon, K. H.

AU - Hammond, E. H.

AU - Lawton, C. A.

AU - Mesic, J. B.

AU - Fu, K. K.

AU - Porter, A. T.

AU - Abrams, R. A.

AU - Shipley, W. U.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70% for those with diploid tumors and 42% for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.

AB - Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70% for those with diploid tumors and 42% for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.

UR - http://www.scopus.com/inward/record.url?scp=0037500178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037500178&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.02.025

DO - 10.1200/JCO.2003.02.025

M3 - Article

VL - 21

SP - 1238

EP - 1248

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -